. "leukemia; age-time-space distribution; synchronous and metachronous occurrence; clinical stages of subsequent cancers"@en . "V\u00FDskyt dal\u0161\u00EDch novotvar\u016F u nemocn\u00FDch s leukemi\u00ED" . . . "V\u00FDskyt dal\u0161\u00EDch novotvar\u016F u nemocn\u00FDch s leukemi\u00ED"@cs . . . . . . "CZ - \u010Cesk\u00E1 republika" . . . "A total of 30,166 cases of leukemia, based in the Czech Cancer Registry in 1976\u20132005, there were notificated 3,937 multiple cases associated with the ocurrence of other neoplasms. Of them there were 2,450 (62.2 %) in males and 1,487 (37.8 %) in females, i.e. 14.7 % cases in males and 11 % in females of total registered leukemia. There were diagnosed 2,064 other neoplasms after 1,715 primary leukemias and 2,642 other primary neoplasms before 2,222 subsequent leukemias. A total of 14 Czech regions were distributed 35.5 % multiple leukemias in three regions (Southern and Northern Moravia, Prague). In the average interval 4.9 years in males and 5.5 years in females followed 35.1 % cancer of skin and melanoma, 16.9 % digestive, 13 % respiratory and 8.4 % urinary system. The expected low representation of advanced clinical stages in subsequent cancers was not confirmed: in males 43.8 % cancer of oral cavity, 41.5 % respiratory, 34.2 % digestive, 10.6 % urinary and 15.7 % genital organs; in females 39.4 % respiratory, 30.6 % urinary, 30 % digestive and 28.2 % genital organs, 25 % breast, 25 % oral cavity. Unfortunatelly a lot of clinical stages are not registered. Before the subsequent leukemias the most frequent were primary cancers of skin and melanoma in 43.6 % as a sign of malignant status. Up to October 2007 in males survived only 12.4 % of primary and 10.3 % subsequent leukemias, respective 19.7 % and 14 % in females. How many other neoplasms will be diagnosed in 8,000 surviving with leukemia, estimated in the Czech Republic in 2015? The analysis of multiple neoplasms should be possible to illuminate the mechanisms of susceptibility to multiple cancers and provide insights into the long-term medical care and preventive interventions that will benefit the growing population of cancer survivors.."@en . "2"^^ . "V\u00FDskyt dal\u0161\u00EDch novotvar\u016F u nemocn\u00FDch s leukemi\u00ED" . . "Z 30 166 p\u0159\u00EDpad\u016F leukemi\u00ED, evidovan\u00FDch v \u010Desk\u00E9m registru n\u00E1dor\u016F v letech 1976\u20132005 bylo 3 937 v\u00EDce\u010Detn\u00FDch p\u0159\u00EDpad\u016F spojeno s v\u00FDskytem jin\u00FDch novotvar\u016F. Z nich se 2 450 (62,2 %) vyskytlo u mu\u017E\u016F a 1 487 (37,8 %) u \u017Een, tj. 14,7% p\u0159\u00EDpad\u016F u mu\u017E\u016F a 11 % u \u017Een ze v\u0161ech evidovan\u00FDch leukemi\u00ED. Po 1 715 prim\u00E1rn\u00EDch leukemi\u00EDch bylo diagnostikov\u00E1no 2 064 jin\u00FDch novotvar\u016F a p\u0159ed 2 222 n\u00E1sledn\u00FDmi leukemiemi 2 642 jin\u00FDch prim\u00E1rn\u00EDch n\u00E1dor\u016F. Ze 14 kraj\u016F se ve t\u0159ech vyskytlo 35,5 % v\u00EDce\u010Detn\u00FDch leukemi\u00ED (Jihomoravsk\u00FD a Severomoravsk\u00FD kraj, Praha). V pr\u016Fm\u011Bru za 4,9 roku u mu\u017E\u016F a 5,5 roku u \u017Een n\u00E1sledovalo 35,1 % n\u00E1dor\u016F k\u016F\u017Ee a melanom, 16,9 % n\u00E1dor\u016F tr\u00E1vic\u00EDch, 13 % d\u00FDchac\u00EDch a 8,4 % mo\u010Dov\u00FDch cest. O\u010Dek\u00E1van\u00FD n\u00EDzk\u00FD po\u010Det pokro\u010Dil\u00FDch klinick\u00FDch stadi\u00ED u n\u00E1sledn\u00FDch n\u00E1dor\u016F se nepotvrdil: u mu\u017E\u016F zahrnovala 43, 8 % n\u00E1dor\u016F dutiny \u00FAstn\u00ED, 41, 5 % d\u00FDchac\u00EDch, 34,2% tr\u00E1vic\u00EDch, 10,6 % mo\u010Dov\u00FDch cest a 15,7 % pohlavn\u00EDch org\u00E1n\u016F; u \u017Een 39,4 % d\u00FDchac\u00EDch, 30,6 % mo\u010Dov\u00FDch, 30 % tr\u00E1vic\u00EDch cest a 28,2 % pohlavn\u00EDch org\u00E1n\u016F, 25 % prs\u016F, 25 % dutiny \u00FAstn\u00ED. Bohu\u017Eel mnoho klinick\u00FDch stadi\u00ED nebylo v registru nahl\u00E1\u0161eno. P\u0159ed n\u00E1sledn\u00FDmi leukemiemi bylo nejv\u00EDce prim\u00E1rn\u00EDch karcinom\u016F k\u016F\u017Ee a melanomu v 43, 6 % p\u0159\u00EDpad\u016F jako ukazatel malign\u00EDho stavu. Do \u0159\u00EDjna 2007 p\u0159e\u017E\u00EDvalo u mu\u017E\u016F jen 12,4 % prim\u00E1rn\u00EDch a 10,3 % n\u00E1sledn\u00FDch leukemi\u00ED, respektive 19,7 % a 14 % u \u017Een. Kolik dal\u0161\u00EDch novotvar\u016F se vyskytne u osmi tis\u00EDc p\u0159e\u017E\u00EDvaj\u00EDc\u00EDch s leukemi\u00ED, o\u010Dek\u00E1van\u00FDch v roce 2015? Rozbory v\u00EDce\u010Detn\u00FDch novotvar\u016F by mohly osv\u011Btlit mechanizmy citlivosti k jejich vzniku a poskytnout n\u00E1hled na dispenz\u00E1rn\u00ED p\u00E9\u010Di a preventivn\u00ED opat\u0159en\u00ED, ze kter\u00FDch budou m\u00EDt prosp\u011Bch rostouc\u00ED po\u010Dty onkologicky nemocn\u00FDch v remisi." . . "RIV/65269705:_____/13:#0002190!RIV14-MZ0-65269705" . "I, N" . . "Z 30 166 p\u0159\u00EDpad\u016F leukemi\u00ED, evidovan\u00FDch v \u010Desk\u00E9m registru n\u00E1dor\u016F v letech 1976\u20132005 bylo 3 937 v\u00EDce\u010Detn\u00FDch p\u0159\u00EDpad\u016F spojeno s v\u00FDskytem jin\u00FDch novotvar\u016F. Z nich se 2 450 (62,2 %) vyskytlo u mu\u017E\u016F a 1 487 (37,8 %) u \u017Een, tj. 14,7% p\u0159\u00EDpad\u016F u mu\u017E\u016F a 11 % u \u017Een ze v\u0161ech evidovan\u00FDch leukemi\u00ED. Po 1 715 prim\u00E1rn\u00EDch leukemi\u00EDch bylo diagnostikov\u00E1no 2 064 jin\u00FDch novotvar\u016F a p\u0159ed 2 222 n\u00E1sledn\u00FDmi leukemiemi 2 642 jin\u00FDch prim\u00E1rn\u00EDch n\u00E1dor\u016F. Ze 14 kraj\u016F se ve t\u0159ech vyskytlo 35,5 % v\u00EDce\u010Detn\u00FDch leukemi\u00ED (Jihomoravsk\u00FD a Severomoravsk\u00FD kraj, Praha). V pr\u016Fm\u011Bru za 4,9 roku u mu\u017E\u016F a 5,5 roku u \u017Een n\u00E1sledovalo 35,1 % n\u00E1dor\u016F k\u016F\u017Ee a melanom, 16,9 % n\u00E1dor\u016F tr\u00E1vic\u00EDch, 13 % d\u00FDchac\u00EDch a 8,4 % mo\u010Dov\u00FDch cest. O\u010Dek\u00E1van\u00FD n\u00EDzk\u00FD po\u010Det pokro\u010Dil\u00FDch klinick\u00FDch stadi\u00ED u n\u00E1sledn\u00FDch n\u00E1dor\u016F se nepotvrdil: u mu\u017E\u016F zahrnovala 43, 8 % n\u00E1dor\u016F dutiny \u00FAstn\u00ED, 41, 5 % d\u00FDchac\u00EDch, 34,2% tr\u00E1vic\u00EDch, 10,6 % mo\u010Dov\u00FDch cest a 15,7 % pohlavn\u00EDch org\u00E1n\u016F; u \u017Een 39,4 % d\u00FDchac\u00EDch, 30,6 % mo\u010Dov\u00FDch, 30 % tr\u00E1vic\u00EDch cest a 28,2 % pohlavn\u00EDch org\u00E1n\u016F, 25 % prs\u016F, 25 % dutiny \u00FAstn\u00ED. Bohu\u017Eel mnoho klinick\u00FDch stadi\u00ED nebylo v registru nahl\u00E1\u0161eno. P\u0159ed n\u00E1sledn\u00FDmi leukemiemi bylo nejv\u00EDce prim\u00E1rn\u00EDch karcinom\u016F k\u016F\u017Ee a melanomu v 43, 6 % p\u0159\u00EDpad\u016F jako ukazatel malign\u00EDho stavu. Do \u0159\u00EDjna 2007 p\u0159e\u017E\u00EDvalo u mu\u017E\u016F jen 12,4 % prim\u00E1rn\u00EDch a 10,3 % n\u00E1sledn\u00FDch leukemi\u00ED, respektive 19,7 % a 14 % u \u017Een. Kolik dal\u0161\u00EDch novotvar\u016F se vyskytne u osmi tis\u00EDc p\u0159e\u017E\u00EDvaj\u00EDc\u00EDch s leukemi\u00ED, o\u010Dek\u00E1van\u00FDch v roce 2015? Rozbory v\u00EDce\u010Detn\u00FDch novotvar\u016F by mohly osv\u011Btlit mechanizmy citlivosti k jejich vzniku a poskytnout n\u00E1hled na dispenz\u00E1rn\u00ED p\u00E9\u010Di a preventivn\u00ED opat\u0159en\u00ED, ze kter\u00FDch budou m\u00EDt prosp\u011Bch rostouc\u00ED po\u010Dty onkologicky nemocn\u00FDch v remisi."@cs . "D\u00EDt\u011B, Petr" . "5"^^ . "5"^^ . "RIV/65269705:_____/13:#0002190" . "Geryk, Edvard" . "The incidence of other neoplasms in patients with leukemia"@en . "Onkologie" . "3" . . "1802-4475" . "7" . "[80E2C089FAC0]" . . . . "115680" . . "The incidence of other neoplasms in patients with leukemia"@en . "V\u00FDskyt dal\u0161\u00EDch novotvar\u016F u nemocn\u00FDch s leukemi\u00ED"@cs .